Jefferies Downgrades Salix Pharmaceuticals To Hold

Analysts at Jefferies downgraded

from Buy to Hold. The price target for Salix Pharmaceuticals has been raised from $149.00 to $173.00. Salix Pharmaceuticals shares have gained 51.17% over the past 52 weeks, while the S&P 500 index has surged 11.47% in the same period. Salix Pharmaceuticals' shares fell 0.54% to $171.54 in pre-market trading.